We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sandoz Group Ag | LSE:0SAN | London | Ordinary Share | CH1243598427 | SANDOZ GROUP ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | |
|---|---|---|---|---|---|
| 0.00 | 0.00% |
| High Price | Low Price | Open Price | Shares Traded | Last Trade |
|---|---|---|---|---|
| 10,423 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 9.65B | 77M | - | N/A | 0 |
| Date | Time | Source | Headline |
|---|---|---|---|
| 17/12/2024 | 06:00 | UKREG | Sandoz takes further steps to resolve legacy US Generic Drug Antitrust.. |
| 15/11/2024 | 06:00 | UKREG | Sandoz receives European Commission approval for Afqlir® (aflibercept),.. |
| 30/10/2024 | 06:00 | UKREG | Sandoz reports third-quarter and nine-month 2024 sales |
| 12/8/2024 | 05:00 | UKREG | Sandoz receives FDA approval for Enzeevu™ (aflibercept-abzv), further.. |
| 08/8/2024 | 05:00 | UKREG | Sandoz reports second-quarter sales and half-year 2024 results |
| 25/7/2024 | 05:00 | UKREG | Sandoz launches biosimilar Pyzchiva® (ustekinumab) across Europe, to treat.. |
| 01/7/2024 | 05:00 | UKREG | FDA approves biosimilar Pyzchiva® (ustekinumab-ttwe), to be commercialized.. |
| 22/5/2024 | 05:00 | UKREG | Sandoz receives European Commission approval for Wyost® and Jubbonti®, the.. |
| 07/5/2024 | 05:00 | UKREG | Sandoz reports first quarter 2024 sales |
| 30/4/2024 | 10:25 | UKREG | Shareholders approve all resolutions proposed by Board of Directors at.. |
1 Year Sandoz Chart |
Intraday Sandoz Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
